The Oncotype DX test is a genetic test that profiles the tumors of women who have early-stage hormone receptor-positive, HER2 negative breast cancer. The test can help predict the risk of your breast cancer returning. After surgery, a piece of the tumor is sent off to be tested. The result is a number otherwise known as the “Oncotype DX score.”
The score determines if a woman is at low, intermediate, or high risk of recurrence and based on that result, whether a woman may benefit from the addition of chemotherapy before receiving hormonal therapy. In general, women who have a low score do not need chemotherapy. Women who have a high score may decrease the risk of the cancer coming back with the addition of chemotherapy.
Read MoreLearn more about SurvivorNet's rigorous medical review process.